MindMed doses first subject in Phase IIb generalized anxiety disorder trial

Mind Medicine (MindMed) has dosed the first subject in its Phase IIb clinical trial of MM-120 to treat generalised anxiety disorder (GAD), a chronic mental health disorder.

A total of 200 GAD subjects will be enrolled in the dose-optimisation, multicentre, parallel, double-blind, randomised, placebo-controlled trial of MM-120.